Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anika Starts New Year With Fidia Acquisition, Direct Sales Plan

This article was originally published in The Gray Sheet

Executive Summary

Anika Therapeutics' acquisition of Fidia Advanced Biopolymers provides a "critical mass" of hyaluronic acid-based products to market in the U.S. alongside its PMA-pending Monovisc single-injection knee osteoarthritis therapy, the firm said

You may also be interested in...

Genzyme’s Synvisc-One approved

Single-injection viscosupplement is approved to treat osteoarthritis of the knee in patients who have failed to respond to more conservative therapy, the firm announces Feb. 26. On Dec. 9, FDA's Orthopedic and Rehabilitation Devices advisory panel recommended approval of Genzyme's PMA supplement for the single-dose version of Synvisc (approved in 1997). Unlike Synvisc-One, Synvisc requires three intra-articular injections at one-week intervals (1"The Gray Sheet" Dec. 15, 2008, p. 13). Genzyme says it will launch Synvisc-One "immediately.

Sun's Halol Site Faces FDA Action

FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.

Dr Reddy’s And Hikma Win Big On US Vascepa Patents

In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts